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Available online 8 March 2016Spinocerebellar ataxia type 3 (SCA3) is a dominantly inherited neurodegenerative disease caused by an expan-
sion of the CAG-repeat in ATXN3. In this study, induced pluripotent stem cells (iPSCs) were generated from
SCA3 patient dermal ﬁbroblasts by electroporation with episomal plasmids encoding L-MYC, LIN28, SOX2, KLF4,
OCT4 and short hairpin RNA targeting P53. The resulting iPSCs had normal karyotype,were free of integrated epi-
somal plasmids, expressed pluripotency markers, could differentiate into the three germ layers in vitro and
retained the disease-causingATXN3mutation. Potentially, this iPSC line could be a useful tool for the investigation
of SCA3 disease mechanisms.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).en
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Spinocerebellar ataxia type 3 (SCA3) is a dominantly inherited neu-
rodegenerative disease caused by a CAG-repeat expanding mutation of
the gene ATXN3 encoding ataxin-3. CAG-repeat length of mutated
alleles can vary from 45 to 87 repeats (Matos et al. 2011). In the current
study, dermal ﬁbroblasts (H249) were derived from a skin biopsy of a
58-year-old man with spinocerebellar ataxia type 3 (SCA3) with 78
CAG-repeats in the disease allele of ATXN3.1 Patient ﬁbroblasts were
reprogrammed to iPSCs by electroporation with three episomal plas-
mids encoding human L-MYC and LIN28, SOX2 and KLF4, and OCT4 com-
bined with a short hairpin RNA for P53 (shP53). The iPSC line described
in this publicationwas termed SCA3.B11. An additional iPSC line termed
SCA3.B1was derived from the same patient and characterized (data not
shown). SCA3.B11 had a numerically and structurally normal karyotype
(46, XY) (Fig. 1A) and no integration of reprogramming plasmids
(Fig. 1B). The pluripotency genes OCT4, NANOG, SOX2 and LIN28 were
upregulated in iPSCs compared to patient ﬁbroblasts (Fig. 1C) and the
gene expression levels were comparable to those of a previously
described positive control iPSC line (Rasmussen et al., 2014). In1 This CAG-repeat length was determined in blood cells at the time of diagnose and dif-
fers from iPSCs and ﬁbroblasts probably because of somatic mosaicism.
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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OCT4, NANOG, TRA-1-60, TRA-1-81, SSEA-3 and SSEA-4 (Fig. 1D), illus-
trating the purity of the iPSC line. Pluripotency was supported by the
ability of SCA3.B11 to differentiate to cells from the three germ layers
in vitro, as shown by ﬂuorescent immunocytochemistry displaying
expression of the endodermal marker α-fetoprotein (AFP), the meso-
dermal marker smooth muscle actin (SMA) and the ectodermal marker
β-III-tubulin (βIIItub) (Fig. 1E). The identity of SCA3.B11was conﬁrmed
by demonstrating expression of both normal and expanded ataxin-3
proteins by western blot (Fig. 1F). Furthermore, the lengths of the
CAG-repeats in the two ataxin-3 alleles were determined to 14 and 74Fig. 1. A.Karyotyping. Representativemetaphase of SCA3.B11 iPSCs.B. Integration analysis. Patie
isolated for qRT-PCR with reprogramming plasmid speciﬁc primers. CT-values were normalize
relative to ﬁbroblasts using the ΔΔCT –method (Mean ± S.D). C. Gene expression of pluripot
2014) were harvested in triplicates and reverse transcribed to cDNA for qRT-PCR. CT-valu
expression was calculated relative to ﬁbroblasts using the ΔΔCT -method (Mean ± S.D). D
ﬂuorescent immunocytochemistry on SCA3.B11 iPSCs. Cell nuclei were stained with Hoechst
endodermal marker α-fetoprotein (AFP), the mesodermal marker smooth muscle actin (SM
bodies. Scalebars: 100 μm. F. Expression of ataxin-3 disease mutation. Western blot showing t
indicate wild type ataxin-3, while black arrowheads show the expanded form of ataxin-3. GAPrepeats in both patient iPSCs and ﬁbroblasts by fragment length analysis
(data not shown).
2. Materials and methods
2.1. Reprogramming of ﬁbroblasts to iPSCs
Written informed consent was obtained from the SCA3 patient and
the study was approved by the regional scientiﬁc ethical committee in
the Capital Region of Denmark (H-4-2011-157). A skin biopsy was
obtained from the forearmof a 58-year-oldmale SCA3patient, dissectedntﬁbroblasts (H249) and SCA3.B11 (B11) iPSCswere harvested induplicates andDNAwas
d to the geometric mean of Hsp90AB1, GUSB and RPL13A and fold change was calculated
ency markers. Patient ﬁbroblasts, SCA3.B11 and K2_shP53 (K2) iPSCs (Rasmussen et al.,
es were normalized to the geometric mean of Hsp90AB1, GUSB and RPL13A and gene
. Protein expression of pluripotency markers. Pluripotency markers were stained by
. Scalebars: 100 μm. E. In vitro differentiation. Fluorescent immunocytochemistry of the
A) and the ectodermal marker β-III-tubulin (βIIItub) in plated iPSC-derived embryoid
he protein expression of ataxin-3 in patient ﬁbroblasts and SCA3.B11. White arrowheads
DH was used to ensure equal loading.
Table 1
qRT-PCR primers.
Target Forward/Reverse primer (5′-3′)
Episomal Plasmids KLF4 Plasmid CCACCTCGCCTTACACATGAAGA
TAGCGTAAAAGGAGCAACATAG
LIN28 Plasmid AGCCATATGGTAGCCTCATGTCCGC
TAGCGTAAAAGGAGCAACATAG
L-MYC
Plasmid
GGCTGAGAAGAGGATGGCTAC
TTTGTTTGACAGGAGCGACAAT
OCT4 Plasmid CATTCAAACTGAGGTAAGGG
TAGCGTAAAAGGAGCAACATAG
SOX2 Plasmid TTCACATGTCCCAGCACTACCAGA
TTTGTTTGACAGGAGCGACAAT
Pluripotency
Markers
LIN28 AGCCATATGGTAGCCTCATGTCCGC
TCAATTCTGTGCCTCCGGGAGCAGGGTA
GG
NANOG TTGGGACTGGTGGAAGAATC
GATTTGTGGGCCTGAAGAAA
OCT4 CCCCAGGGCCCCATTTTGGTACC
ACCTCAGTTTGAATGCATGGGAGAGC
SOX2 TTCACATGTCCCAGCACTACCAGA
TCACATGTGTGAGAGGGGCAGTGTGC
House-Keeping
Genes
GUSB TCCGCGCCGACTTCTCTGACA
AAATGCCGCAGACGCCAGTCC
HSP90AB1 TCCGGCGCAGTGTTGGGAC
TCCATGGTGCACTTCCTCAGGC
RPL13A TTCCAAGCGGCTGCCGAAGA
TTCCGGCCCAGCAGTACCTGT
Table 2
Primary antibodies.
Marker of Antigen Specie Dilution Company, Catnr.
Pluripotency NANOG Rabbit 1:500 Perprotech, 500-P236
OCT4 Goat 1:200 Santa cruz, sc8628
SSEA-3 Rat 1:200 Biolegend, MC-631
SSEA-4 Mouse 1:200 Biolegend, MC813–70
TRA-1-60 Mouse 1:200 Biolegend, 330,602
TRA-1-81 Mouse 1:200 Biolegend, 330,702
Mesoderm SMA Mouse 1:500 Dako, M0851
Endoderm AFP Rabbit 1:500 Dako, A0008
Ectoderm βIIItub Mouse 1:4000 Sigma-Aldrich, T8660
Other Ataxin-3 Mouse 1:1000 Millipore, MAB5360
GAPDH Rabbit 1:1000 Abcam, Ab9485
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medium (DMEM) high glucose (Lonza) supplemented with 10% fetal
calf serum (FBS) (Biological Industries), 2 mM L-glutamine (Lonza)
and 1% penicillin–streptomycin (ThermoFisher Scientiﬁc) for 10 days
at 37 °C and 5% CO2 to allow ﬁbroblasts to grow out. Subsequently,
ﬁbroblasts were expanded in ﬁbroblast medium with 2 ng/ml FGF2
(Sigma-Aldrich). The reprogramming procedure was adopted from a
method described by Rasmussen et al. (Rasmussen et al., 2014). In
brief, 1 x 105 ﬁbroblasts were electroporated with 1 μg 1:1:1 mix of
three episomal plasmids pCXLE-hUL (L-MYC, LIN28, Adgene #27080),
pCXLE-hSK (SOX2, KLF4, Adgene #27078) and pCXLE-hOCT4-shp53-F
(OCT4, shP53, Adgene #27077) (Okita et al. 2011) applying the Neon
transfection system (Invitrogen) with 2 × 20 ms pulses of 1200 V.
After electroporation, the cells were plated in ﬁbroblast medium with-
out penicillin–streptomycin. From day 1–8 1% penicillin–streptomycin
was added to the medium. On day 7 the cells were split 1:2 with tryp-
sin–EDTA (Sigma-Aldrich) and seeded on hESC-qualiﬁed matrigel (BD
Biosciences). From day 8 the cells were cultured in mTeSR1 (Stem Cell
Technologies) with 0.1% penicillin–streptomycin at 37 °C in 5% CO2,
5% O2 and 90% N2. On day 23–31 single emerging iPSC colonies were
manually cut and passaged for expansion. From passage 3 the cells
were split with dispase (ThermoFisher Scientiﬁc) every 4–7 days. The
iPSCs were frozen in mFreSR1 (Stem Cell Technologies) with 10 μM
rock inhibitor (Sigma-Aldrich). The control iPSC cell line K2_shp53
generated from a healthy donor was previously characterized by
Rasmussen et al. (Rasmussen et al., 2014) and banked in the European
Bank of induced Pluripotent Stem Cells (EBiSC) as BIONi010-B.
2.2. Karyotyping
iPSCs were treated for 1 h with KaryoMAX colcemid (ThermoFisher
Scientiﬁc), harvested and ﬁxed in 25% acetic acid and 75% methanol.
Karyotyping was performed on G-banded metaphase chromosomes
using standard procedures. A minimum of 10 metaphases were exam-
ined per sample with an approximate resolution of 400–450 bands
per haploid genome.
2.3. Integration analysis
DNA was isolated using the DNeasy blood & tissue kit (Qiagen)
according to manufacturer's instructions. The three reprogramming
plasmids (pCXLE-hUL, pCXLE-hSK and pCXLE-hOCT4-shp53-F) were
used as positive controls to verify function of the plasmid speciﬁc
primers (data not shown). qRT-PCR reactions were performed with
2× diluted SsoFast EvaGreen supermix (Bio-Rad). The primers are listed
in Table 1. CT -values were normalized to the geometric mean of the
three housekeeping genes Hsp90AB1, GUSB and RPL13A using the Δ
ΔCT -method.
2.4. Quantitative real time polymerase chain reaction (qRT-PCR).
RNA isolation was performed with the RNAeasy mini kit (Qiagen)
according to manufacturer's protocol. 0.5 μg RNA/reaction was reverse
transcribed with TaqMan reverse transcription reagents (Applied
Biosystems). qRT-PCR reactions were run with 2× diluted SsoFast
EvaGreen supermix (Bio-Rad). Primers are listed in Table 1. CT -values
were normalized to the geometric mean of the housekeeping genes
Hsp90AB1, GUSB and RPL13A using the ΔΔCT -method.
2.5. In vitro differentiation
iPSC colonies were detached with dispase in large clumps and
transferred to ultra-low adherent plates (Stem Cell Technologies) in
mTeSR1 with 10 μM rock inhibitor. After two days the medium was
replaced with embryoid body (EB) medium consisting of DMEMF12
(Sigma-Aldrich) with 20% knockout serum replacement (ThermoFisherScientiﬁc), 1× non-essential amino acids (ThermoFisher Scientiﬁc),
2 mM glutamax (ThermoFisher Scientiﬁc), 0.1 mM 2-mercaptoethanol
(ThermoFisher Scientiﬁc) and 1% penicillin–streptomycin. 7 days after
split EBs were seeded on 0.1% gelatin (Sigma-Aldrich) and cultured for
2 weeks in differentiation medium consisting of DMEM F12 supple-
mented with 10% FBS, 2 mM glutamax and 1% penicillin–streptomycin.
2.6. Fluorescent immunocytochemistry
iPSCs and plated EBs were ﬁxed for 20 min in 4% paraformaldehyde
(Sigma-Aldrich) and washed in PBS. Then the cells were permeabilized
with 0.1% triton X-100 (Sigma-Aldrich) for 15 min and blocked with 5%
normal donkey serum (Millipore, S30) and 1% BSA (Roche) for 30 min.
Subsequently, the cells were stained by standard immunoﬂuorescence
procedures. Primary antibodies are listed in Table 2. The following sec-
ondary antibodies were used in a 1:200 dilution: Alexa 594 donkey-
anti-rat, Alexa 488 donkey-anti-mouse, Alexa 594 donkey-anti-rabbit
and Alexa 594 donkey-anti-goat (all from ThermoFisher Scientiﬁc).
Additionally, cell nuclei were stained with 0.7 μg/ml Hoechst. Images
of in vitro differentiated EBs were captured with an Evos ﬂ ﬂuorescent
microscope, while images of iPSCs were taken with a Nikon Eclipse Ti
4.10 microscope, Yokogawa CSU-X1 spinning disk confocal scanner. In
parallel with staining of SCA3.B11 iPSCs, patient ﬁbroblasts (H249)
and the characterized iPSC line K2_shP53 were used as a negative and
positive controls, respectively (data not shown).
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Cells were lysed in Ripa buffer (Sigma-Aldrich) supplemented with
1 complete protease inhibitor cocktail tablet (Roche)/40 ml for 10 min
and subsequently spun at 15,000×g for 10 min. Then 100 mM DTT
(Sigma-Aldrich) and NuPAGE LDS Sample Buffer (ThermoFisher
Scientiﬁc) corresponding to one fourth of the total sample volume
were added. The samples were boiled and run on NuPAGE Novex 4–
12% Bis-Tris precast SDS-PAGE gels (ThermoFisher Scientiﬁc) and sub-
sequently blotted onto Immobilin-FL PVDF membranes (Merck
Millipore). The membranes were blocked in odyssey blocking buffer
(LI-COR Biosciences) and incubated with primary antibody (Table 2)
ON at 4 °C. After washing with PBS/0.1% tween-20 (Merck Millipore)
the membranes were probed with secondary antibodies Alexa Fluor
680 goat-anti-rabbit IgG diluted 1:20,000 (A21077) and Alexa Flour
800 goat-anti-mouse diluted 1:10,000 (926–32,210) (both from
ThermoFisher Scientiﬁc) for 1 h at RT. Emitted light was detected with
an infrared Odyssey CLx scanner (LI-COR Odyssey Biosystems).
2.8. Fragment length analysis
DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen)
according to manufacturer's protocol. The CAG-repeat of the ATXN3
gene was ampliﬁed by PCR with the primers: 5′-Fam- TGGCCTTTCACA
TGGATGTGA-3′ and 5′-CCAGTGACTACTTTGATTCG-3′. 1 μl diluted PCR
product, 10 μl formamide (ThermoFisher Scientiﬁc) and 0.5 μl
SizeStandard LIZ-600 (ThermoFisher Scientiﬁc) were mixed and frag-
ment length analysis was carried out by capillary electrophoresis onan ABI 3130 Genetic Analyzer. Data were analyzed with the Peak scan-
ner software v1.0 (Applied Biosystems).
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